Mariko Ishibashi
Sendagi, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Inflammatory cytokine interleukin-18 prevents murine miscarriage by inducing appropriate inflammation.
Journal: Scientific reports
Published: October 15, 2024
Immune microenvironment and immunotherapy resistance in multiple myeloma
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: October 02, 2024
A whole gamma imaging prototype for higher quantitative imaging of89Zr-labeled antibodies in a tumor mouse model.
Journal: Physics in medicine and biology
Published: June 14, 2024
Gelsolin alleviates rheumatoid arthritis by negatively regulating NLRP3 inflammasome activation.
Journal: Cell death and differentiation
Published: April 30, 2024
Current and Future PET Imaging for Multiple Myeloma.
Journal: Life (Basel, Switzerland)
Published: June 07, 2023
The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma.
Journal: Experimental hematology
Published: August 10, 2022
Clinicopathologic Characteristics and A20 Mutation in Primary Thyroid Lymphoma.
Journal: Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
Published: November 29, 2021
Epigenetic Priming with Decitabine Augments the Therapeutic Effect of Cisplatin on Triple-Negative Breast Cancer Cells through Induction of Proapoptotic Factor NOXA.
Journal: Cancers
Published: November 16, 2021
Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple Myeloma.
Journal: Cancers
Published: November 28, 2020
SLAM family proteins as therapeutic targets in multiple myeloma
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: August 08, 2020
The SLAMF3 rs509749 polymorphism correlates with malignant potential in multiple myeloma.
Journal: Experimental hematology
Published: May 01, 2020
Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
Journal: Molecular cancer therapeutics
Published: March 31, 2020
Last Updated: 09/26/2026